ATE275134T1 - 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel - Google Patents

4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel

Info

Publication number
ATE275134T1
ATE275134T1 AT99965907T AT99965907T ATE275134T1 AT E275134 T1 ATE275134 T1 AT E275134T1 AT 99965907 T AT99965907 T AT 99965907T AT 99965907 T AT99965907 T AT 99965907T AT E275134 T1 ATE275134 T1 AT E275134T1
Authority
AT
Austria
Prior art keywords
antiviral agents
quinolinecarboxamide
dihydro
oxo
substituted
Prior art date
Application number
AT99965907T
Other languages
English (en)
Inventor
Steven Ronald Turner
Joseph Walter Strohbach
Suvit Thaisrivongs
Valerie A Vaillancourt
Mark E Schnute
Allen Scott
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE275134T1 publication Critical patent/ATE275134T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
AT99965907T 1999-01-08 1999-12-22 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel ATE275134T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11511399P 1999-01-08 1999-01-08
US13839099P 1999-06-09 1999-06-09
US14061499P 1999-06-23 1999-06-23
PCT/US1999/027959 WO2000040563A1 (en) 1999-01-08 1999-12-22 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Publications (1)

Publication Number Publication Date
ATE275134T1 true ATE275134T1 (de) 2004-09-15

Family

ID=27381602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965907T ATE275134T1 (de) 1999-01-08 1999-12-22 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel

Country Status (28)

Country Link
US (1) US6248736B1 (de)
EP (1) EP1140851B1 (de)
JP (1) JP2002534417A (de)
KR (1) KR20010101428A (de)
CN (1) CN1132818C (de)
AT (1) ATE275134T1 (de)
AU (1) AU2158300A (de)
BR (1) BR9916781A (de)
CA (1) CA2353634A1 (de)
CO (1) CO5150150A1 (de)
CZ (1) CZ20012458A3 (de)
DE (1) DE69919897T2 (de)
EA (1) EA004043B1 (de)
ES (1) ES2228162T3 (de)
HK (1) HK1041879A1 (de)
HU (1) HUP0105142A3 (de)
ID (1) ID29452A (de)
IL (1) IL144170A0 (de)
MY (1) MY118904A (de)
NO (1) NO320396B1 (de)
NZ (1) NZ512823A (de)
PE (1) PE20001337A1 (de)
PL (1) PL348769A1 (de)
PT (1) PT1140851E (de)
SK (1) SK8312001A3 (de)
TR (1) TR200101893T2 (de)
TW (1) TW593281B (de)
WO (1) WO2000040563A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2004520424A (ja) 2001-03-01 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての置換型キノリンカルボキサミド
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
US20040176366A1 (en) * 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
WO2004019932A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
TWI248928B (en) 2002-11-20 2006-02-11 Japan Tobacco Inc 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
CN100471842C (zh) 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP1758581A1 (de) 2004-05-21 2007-03-07 Japan Tobacco, Inc. Kombinationen aus einem 4-isochinolon-derivat und anti-hiv-mitteln
EP1773816B1 (de) 2004-06-24 2015-01-07 Vertex Pharmaceuticals Incorporated Modulatoren von Transportern der ATP bindenden Kassette
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
EP1978960A4 (de) * 2006-02-01 2009-12-02 Japan Tobacco Inc Verwendung von 6-(3-chlor-2-fluorbenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl[-7-methoxy-4-oxo-1,4-dihydrochinolin-3-carboxylsäure oder einem salz daraus zur behandlung einer retrovireninfektion
AU2007223260C1 (en) * 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
DE102008036099B4 (de) 2008-08-04 2014-02-13 Steag Power Saar Gmbh Entstickungsanlage
WO2010108162A1 (en) 2009-03-20 2010-09-23 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
MX342119B (es) * 2010-08-27 2016-09-14 Grünenthal Gmbh * 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EP2819670A1 (de) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzung und verabreichung davon
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
CN105209453B (zh) 2012-10-16 2017-06-20 詹森药业有限公司 ROR‑γ‑T的亚甲基连接的喹啉基调节剂
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593810B1 (fr) * 1986-01-24 1988-04-22 Sanofi Sa Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
JPH06502845A (ja) * 1990-09-07 1994-03-31 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
DE69115692T2 (de) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermisch übertragbare fluoreszierende Verbindungen
MX9800922A (es) * 1995-08-02 1998-05-31 Darwin Discovery Ltd Quinolonas y su uso terapeutico.
EP0876349B1 (de) 1995-10-19 2002-09-11 Takeda Chemical Industries, Ltd. Chinolinderivate als gnrh antagonisten
IL129344A0 (en) 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
US6093732A (en) 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents

Also Published As

Publication number Publication date
KR20010101428A (ko) 2001-11-14
JP2002534417A (ja) 2002-10-15
MY118904A (en) 2005-02-28
EA004043B1 (ru) 2003-12-25
HUP0105142A2 (hu) 2002-04-29
US6248736B1 (en) 2001-06-19
BR9916781A (pt) 2001-12-04
WO2000040563A1 (en) 2000-07-13
NO320396B1 (no) 2005-11-28
HK1041879A1 (en) 2002-07-26
CA2353634A1 (en) 2000-07-13
CN1332729A (zh) 2002-01-23
NO20013379D0 (no) 2001-07-06
NZ512823A (en) 2003-10-31
SK8312001A3 (en) 2001-12-03
CZ20012458A3 (cs) 2001-12-12
NO20013379L (no) 2001-07-06
CO5150150A1 (es) 2002-04-29
DE69919897D1 (en) 2004-10-07
TR200101893T2 (tr) 2001-11-21
PE20001337A1 (es) 2000-11-23
ES2228162T3 (es) 2005-04-01
HUP0105142A3 (en) 2002-05-28
CN1132818C (zh) 2003-12-31
IL144170A0 (en) 2002-05-23
PT1140851E (pt) 2004-12-31
EA200100755A1 (ru) 2001-12-24
ID29452A (id) 2001-08-30
TW593281B (en) 2004-06-21
EP1140851B1 (de) 2004-09-01
PL348769A1 (en) 2002-06-17
EP1140851A1 (de) 2001-10-10
AU2158300A (en) 2000-07-24
DE69919897T2 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
ATE275134T1 (de) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
DK0639186T3 (da) Taxolderivater
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
DE69522703D1 (de) Aminotetrazol-derivate verwendbar als stickstoff-oxid-synthase inhibitoren
IT1224416B (it) Chelanti macrociclici e loro chelati
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
PE34996A1 (es) Nuevo derivado de pirrocarbazol
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
ES2123756T3 (es) Derivados de piperazina.
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
DE69329618D1 (de) 3-oxo-1,4-benzothiazin-derivate
ATE119523T1 (de) Isochinolinderivate und ihre salze als proteasehemmer.
ATE148462T1 (de) Isoxazole derivate als lichtschutzmittel
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
ECSP993294A (es) 4- oxo-1,4- dihidro -3-quinoleincarboxamidas como agentes antivirales

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140851

Country of ref document: EP

REN Ceased due to non-payment of the annual fee